BENJAMIN HAYDEN: Open Payments
NPI 1841236437 · MANGHAM, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$989 in 12 payments from 11 companies in 2025. Trend: 2023 $1,402 · 2024 $460 · 2025 $989
Food & beverage: $989
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 1 | $129 |
| Insulet Corporation | 1 | $124 |
| AstraZeneca Pharmaceuticals LP | 1 | $122 |
| Astellas Pharma US Inc | 1 | $120 |
| Novo Nordisk Inc | 1 | $103 |
| Boston Scientific Corporation | 1 | $92 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $83 |
| Stryker Corporation | 1 | $82 |
| Amgen Inc. | 1 | $80 |
| Vanda Pharmaceuticals Inc. | 2 | $36 |
Products named: Omnipod, BREZTRI, Veozah, Ozempic, Intracept, JARDIANCE, OTEZLA, FANAPT.
Industry payments across LA — which companies pay providers there.
